The following is a summary of “Unveiling the Prevalence and Impact of Silent Rhinovirus Infection in Chronic Rhinosinusitis with Nasal Polyps,” published in the January 2025 issue of Annals of Allergy ...

A few baseline characteristics can predict the need for recurrent endoscopic sinus surgery among patients with CRSwNP.

London: GSK plc has announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorisation Application for the use of depemokimab in two indications. The submitted ...

GSK plc announced that the European Medicines Agency has accepted for review the Marketing Authorisation Application for the use of depemokimab in two indications. The submitted indications are for ...

Thymic stromal lymphopoietin (TSLP) and interleukin (IL)-4 levels are elevated in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) and correlated with increased preoperative fractional ...

If approved, depemokimab would be the first ultra-long-acting biologic with a six-month dosing interval for the treatment of asthma with type 2 inflammation and chronic rhinosinusitis with nasal ...

LONDON - GSK plc (LSE/NYSE: GSK) has announced the acceptance of regulatory filings in China and Japan for depemokimab, a new biologic treatment for asthma with type 2 inflammation and chronic ...